SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Daniel Luedecke, Daniel Schöttle, Anne Karow, Martin Lambert, Dieter Naber, Post-Injection Delirium/Sedation Syndrome in Patients Treated with Olanzapine Pamoate: Mechanism, Incidence, and Management, CNS Drugs, 2015, 29, 1, 41

    CrossRef

  2. 2
    Harin Kim, Jungsun Lee, Changyoon Kim, Yeonho Joo, The Drug Adherence and Treatment Effect of the Paliperidone Long Acting Injection, Journal of Korean Neuropsychiatric Association, 2015, 54, 1, 69

    CrossRef

  3. 3
    Sara Montminy Paquette, Had Dawit, Magali B. Hickey, Elaine Merisko-Liversidge, Örn Almarsson, Daniel R. Deaver, Long-Acting Atypical Antipsychotics: Characterization of the Local Tissue Response, Pharmaceutical Research, 2014, 31, 8, 2065

    CrossRef

  4. 4
    Tatiana Dilla, Jörgen Möller, Paul O’Donohoe, María Álvarez, José A Sacristán, Michael Happich, Antje Tockhorn, Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison, BMC Psychiatry, 2014, 14, 1, 298

    CrossRef

  5. You have free access to this content5
    Hee Ryung Wang, Young Sup Woo, Won-Myong Bahk, Atypical antipsychotics in the treatment of delirium, Psychiatry and Clinical Neurosciences, 2013, 67, 5
  6. 6
    Vladan Novakovic, Tymaz Adel, Eric Peselow, Jean-Pierre Lindenmayer, Long-Acting Injectable Antipsychotics and the Development of Postinjection Delirium/Sedation Syndrome (PDSS), Clinical Neuropharmacology, 2013, 36, 2, 59

    CrossRef

  7. 7
    Anna-Sophia Rauch, W. Wolfgang Fleischhacker, Long-Acting Injectable Formulations of New-Generation Antipsychotics: A Review from a Clinical Perspective, CNS Drugs, 2013, 27, 8, 637

    CrossRef

  8. 8
    Leslie Citrome, New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia, Expert Review of Neurotherapeutics, 2013, 13, 7, 767

    CrossRef

  9. 9
    Susan D’Souza, Jabar A. Faraj, Stefano Giovagnoli, Patrick P. DeLuca, Preparation, Characterization, and In Vivo Evaluation of Olanzapine Poly(D,L-lactide-co-glycolide) Microspheres, Journal of Pharmaceutics, 2013, 2013, 1

    CrossRef

  10. 10
    Alkomiet Hasan, Peter Falkai, Thomas Wobrock, Jeffrey Lieberman, Birte Glenthoj, Wagner F. Gattaz, Florence Thibaut, Hans-Jürgen Möller, World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects, World Journal of Biological Psychiatry, 2013, 14, 1, 2

    CrossRef

  11. 11
    Pierre Chue, James Chue, A review of olanzapine pamoate, Expert Opinion on Pharmacotherapy, 2012, 13, 11, 1661

    CrossRef

  12. 12
    Ricardo Millán-González, Consentimientos informados y aprobación por parte de los comités de ética en los estudios de antipsicóticos atípicos para el manejo del delírium, Revista Colombiana de Psiquiatría, 2012, 41, 1, 150

    CrossRef

  13. 13
    Stefania Ruiu, Maria Antonietta Casu, Gianluca Casu, Sara Piras, Giorgio Marchese, Effects of controlled-release formulations of atypical antipsychotics on functioning and quality of life of schizophrenic individuals, Expert Opinion on Pharmacotherapy, 2012, 13, 11, 1631

    CrossRef

  14. 14
    Leslie Citrome, Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, Expert Opinion on Drug Metabolism & Toxicology, 2012, 8, 7, 873

    CrossRef

  15. 15
    David J. Castle, Nga Tran, Deirdre Alderton, Pharmacological and Psychosocial Treatments in Schizophrenia, 2012,

    CrossRef

  16. 16
    Nga Tran, Deirdre Alderton, Pharmacological and Psychosocial Treatments in Schizophrenia, Third Edition, 2012,

    CrossRef

  17. 17
    Dieter Naber, Olanzapine pamoate for the treatment of schizophrenia, Expert Opinion on Pharmacotherapy, 2011, 12, 4, 627

    CrossRef

  18. 18
    Antonio Leyva-Pérez, Jose R. Cabrero-Antonino, Avelino Corma, Bifunctional solid catalysts for chemoselective hydrogenation–cyclisation–amination cascade reactions of relevance for the synthesis of pharmaceuticals, Tetrahedron, 2010, 66, 41, 8203

    CrossRef

  19. 19
    Leslie Citrome, Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion, Expert Opinion on Drug Metabolism & Toxicology, 2010, 6, 12, 1551

    CrossRef

  20. 20
    James E. Frampton, Olanzapine Long-Acting Injection, Drugs, 2010, 70, 17, 2289

    CrossRef

  21. 21
    L. Citrome, Paliperidone palmitate – review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication, International Journal of Clinical Practice, 2010, 64, 2
  22. 22
    Wolfgang Gaebel, Andreas Schreiner, Paul Bergmans, Rosario de Arce, Frédéric Rouillon, Joachim Cordes, Lars Eriksson, Enrico Smeraldi, Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial, Neuropsychopharmacology, 2010, 35, 12, 2367

    CrossRef

  23. 23
    P. M. Haddad, M. Taylor, O. S. Niaz, First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies, The British Journal of Psychiatry, 2009, 195, 52, S20

    CrossRef

  24. 24
    David E. Kemp, Fatih Canan, Benjamin I. Goldstein, Roger S. McIntyre, Long-acting risperidone: a review of its role in the treatment of bipolar disorder, Advances in Therapy, 2009, 26, 6, 588

    CrossRef

  25. 25
    Leslie Citrome, Joshua T Kantrowitz, Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?, Expert Review of Neurotherapeutics, 2009, 9, 7, 1045

    CrossRef

  26. You have free access to this content26
    D. M. Taylor, Olanzapine pamoate – blockbuster or damp squib?, International Journal of Clinical Practice, 2009, 63, 4
  27. 27
    L. Citrome, Posters can be a sticking point: Letter in response to comments by Akhras et al., International Journal of Clinical Practice, 2009, 63, 6
  28. 28
    The Maudsley Prescribing Guidelines, Tenth Edition, 2009,

    CrossRef